I would advise caution when weighing results like these from pharmaceutical companies. While I haven't spent any time digging into the specifics of their pipeline where Cannabidiol is being used in some form or other (except the observation that they were using purified, not broad spectrum), I have noticed that most of these companies are attempting to isolate only certain compounds that may enable them to patent a drug derived from their research.
Some of them have even thrown some of their capital around and pulled some strings attached to certain federal agencies that they might inject confusing legal language in order to "interfere" with the cannabinoid/cannabidiol market, which is growing much more rapidly than their research could otherwise keep pace with. Personally, I don't trust big pharma at all.
The CBD that Rocky Mountain High Brands will be bringing to market is essentially the broad spectrum, or whole plant formula. That's much closer to what early success was actually achieved with, at least in terms of the treatment of seizures and other nervous system ailments. Some of those ailments will respond to or be prevented by long term treatment with full spectrum cannabinoids like those we're about to bring to market.
As with any health ailments, it takes time to discover the most effective approach even with the same compound, let alone with numerous variations of a broad spectrum of compounds. Won't happen overnight, that's for sure. All the more reason for consumers to stick with the whole plant-derived products, at least for now.
Pharmaceutical companies could experience many disappointments in their efforts to find a solitary component isolated from the broad spectrum. In the long haul, it may be found that the best approach always has been and always will be the CBD along with the chemical contents of the whole plant. This is not what pharmaceutical companies are hoping for, because they can't patent the ingredients in their full spectral entirety, or in other words, the whole plant.
The other problem with very specific clinical trials is that there are so many variables that must be accounted for in order to apply the outcome of those trials against the outcome of other similar trials, such as those that were successful using the broad spectrum approach with cannabinoids, with and without THC or higher than normal concentrations of CBD.
Some of the ventures of the pharma world can easily be misleading if their results are taken "out of context", or mistakes were made in attaining the results. The facts will emerge over time as the result of a large number of clinical trials conducted at unbiased research facilities by professionals only interested in the truth.
Some of them have even thrown some of their capital around and pulled some strings attached to certain federal agencies that they might inject confusing legal language in order to "interfere" with the cannabinoid/cannabidiol market, which is growing much more rapidly than their research could otherwise keep pace with. Personally, I don't trust big pharma at all.
The CBD that Rocky Mountain High Brands will be bringing to market is essentially the broad spectrum, or whole plant formula. That's much closer to what early success was actually achieved with, at least in terms of the treatment of seizures and other nervous system ailments. Some of those ailments will respond to or be prevented by long term treatment with full spectrum cannabinoids like those we're about to bring to market.
As with any health ailments, it takes time to discover the most effective approach even with the same compound, let alone with numerous variations of a broad spectrum of compounds. Won't happen overnight, that's for sure. All the more reason for consumers to stick with the whole plant-derived products, at least for now.
Pharmaceutical companies could experience many disappointments in their efforts to find a solitary component isolated from the broad spectrum. In the long haul, it may be found that the best approach always has been and always will be the CBD along with the chemical contents of the whole plant. This is not what pharmaceutical companies are hoping for, because they can't patent the ingredients in their full spectral entirety, or in other words, the whole plant.
The other problem with very specific clinical trials is that there are so many variables that must be accounted for in order to apply the outcome of those trials against the outcome of other similar trials, such as those that were successful using the broad spectrum approach with cannabinoids, with and without THC or higher than normal concentrations of CBD.
Some of the ventures of the pharma world can easily be misleading if their results are taken "out of context", or mistakes were made in attaining the results. The facts will emerge over time as the result of a large number of clinical trials conducted at unbiased research facilities by professionals only interested in the truth.
10
